Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.01
HGR's Cash to Debt is ranked lower than
52% of the 299 Companies
in the Global Medical Care industry.

( Industry Median: 0.19 vs. HGR: 0.01 )
HGR' s 10-Year Cash to Debt Range
Min: 0   Max: 0.86
Current: 0.01

0
0.86
Equity to Asset 0.44
HGR's Equity to Asset is ranked higher than
74% of the 302 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. HGR: 0.44 )
HGR' s 10-Year Equity to Asset Range
Min: 0.2   Max: 0.79
Current: 0.44

0.2
0.79
Interest Coverage 5.06
HGR's Interest Coverage is ranked higher than
69% of the 183 Companies
in the Global Medical Care industry.

( Industry Median: 4.80 vs. HGR: 5.06 )
HGR' s 10-Year Interest Coverage Range
Min: 0.43   Max: 13.53
Current: 5.06

0.43
13.53
F-Score: 4
Z-Score: 2.25
WACC vs ROIC
10.27%
6.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 11.02
HGR's Operating margin (%) is ranked higher than
81% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 9.26 vs. HGR: 11.02 )
HGR' s 10-Year Operating margin (%) Range
Min: 2.59   Max: 15.73
Current: 11.02

2.59
15.73
Net-margin (%) 5.53
HGR's Net-margin (%) is ranked higher than
78% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 4.62 vs. HGR: 5.53 )
HGR' s 10-Year Net-margin (%) Range
Min: -4.11   Max: 7.34
Current: 5.53

-4.11
7.34
ROE (%) 10.23
HGR's ROE (%) is ranked higher than
76% of the 287 Companies
in the Global Medical Care industry.

( Industry Median: 7.86 vs. HGR: 10.23 )
HGR' s 10-Year ROE (%) Range
Min: -14.17   Max: 15.04
Current: 10.23

-14.17
15.04
ROA (%) 4.51
HGR's ROA (%) is ranked higher than
78% of the 305 Companies
in the Global Medical Care industry.

( Industry Median: 3.18 vs. HGR: 4.51 )
HGR' s 10-Year ROA (%) Range
Min: -3.25   Max: 7.58
Current: 4.51

-3.25
7.58
ROC (Joel Greenblatt) (%) 28.10
HGR's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 13.15 vs. HGR: 28.10 )
HGR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 8.55   Max: 50.5
Current: 28.1

8.55
50.5
Revenue Growth (3Y)(%) 6.00
HGR's Revenue Growth (3Y)(%) is ranked higher than
72% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. HGR: 6.00 )
HGR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7.3   Max: 38.3
Current: 6

-7.3
38.3
EBITDA Growth (3Y)(%) 22.30
HGR's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 190 Companies
in the Global Medical Care industry.

( Industry Median: 6.40 vs. HGR: 22.30 )
HGR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -24.7   Max: 51.5
Current: 22.3

-24.7
51.5
EPS Growth (3Y)(%) 41.20
HGR's EPS Growth (3Y)(%) is ranked higher than
92% of the 181 Companies
in the Global Medical Care industry.

( Industry Median: 9.50 vs. HGR: 41.20 )
HGR' s 10-Year EPS Growth (3Y)(%) Range
Min: -21.1   Max: 44.2
Current: 41.2

-21.1
44.2
» HGR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

HGR Guru Trades in Q1 2014

Jim Simons 25,400 sh (New)
Joel Greenblatt 197,842 sh (+585.55%)
HOTCHKIS & WILEY 756,400 sh (+64.9%)
John Keeley 1,616,914 sh (-0.14%)
» More
Q2 2014

HGR Guru Trades in Q2 2014

Paul Tudor Jones 8,400 sh (New)
HOTCHKIS & WILEY 874,600 sh (+15.63%)
Jim Simons Sold Out
Joel Greenblatt Sold Out
John Keeley 1,541,874 sh (-4.64%)
» More
Q3 2014

HGR Guru Trades in Q3 2014

John Rogers 161,420 sh (New)
HOTCHKIS & WILEY 2,040,900 sh (+133.35%)
Paul Tudor Jones 17,600 sh (+109.52%)
John Keeley Sold Out
» More
Q4 2014

HGR Guru Trades in Q4 2014

HOTCHKIS & WILEY 3,416,494 sh (+67.4%)
John Rogers 253,785 sh (+57.22%)
Paul Tudor Jones 12,563 sh (-28.62%)
» More
» Details

Insider Trades

Latest Guru Trades with HGR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
HOTCHKIS & WILEY 2014-12-31 Add 67.4%0.1%$19.58 - $24.19 $ 25.8920%3416494
John Rogers 2014-12-31 Add 57.22%0.02%$19.58 - $24.19 $ 25.8920%253785
John Keeley 2014-09-30 Sold Out 0.87%$20.68 - $32.31 $ 25.892%0
HOTCHKIS & WILEY 2014-09-30 Add 133.35%0.09%$20.68 - $32.31 $ 25.892%2040900
John Rogers 2014-09-30 New Buy0.04%$20.68 - $32.31 $ 25.892%161420
Joel Greenblatt 2014-06-30 Sold Out 0.1%$29.01 - $35.12 $ 25.89-20%0
Joel Greenblatt 2014-03-31 Add 585.55%0.09%$32.25 - $40.47 $ 25.89-29%197842
HOTCHKIS & WILEY 2014-03-31 Add 64.9%0.04%$32.25 - $40.47 $ 25.89-29%756400
John Keeley 2013-12-31 Add 14.24%0.14%$32.79 - $39.58 $ 25.89-29%1619225
HOTCHKIS & WILEY 2013-12-31 Add 30.28%0.02%$32.79 - $39.58 $ 25.89-29%458700
HOTCHKIS & WILEY 2013-09-30 New Buy0.06%$30.46 - $36.92 $ 25.89-22%352100
Joel Greenblatt 2013-09-30 Add 50.97%0.01%$30.46 - $36.92 $ 25.89-22%28084
Joel Greenblatt 2012-12-31 New Buy0.03%$22.74 - $28.45 $ 25.890%18392
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Hanger Inc

Hanger: A favorable aging demography trend
My approach to investment is to first identify a good business and then assess what is a reasonable valuation for the business. In general, I will come across some near-term risks, which cause my target companies to trade below my targeted valuation. For some of my targeted companies, I can anticipate whether the near-term issues can be resolved soon. For some others, I might not know whether the near-term issues will be resolved. However, the valuations sometimes have already reflected a good degree of negatives in the stocks. Today, Hanger (NYSE:HGR) is one of my targeted companies under the latter scenario. My analysis illustrates that HGR trades close to the bottom range of its historical valuation metrics, and HGR is a very solid company with good demography macro trend in its favor. For high-risk tolerant investors, I believe that HGR should be able to navigate through the current tough medical environment and the auditing issues. With patience and an eye to the long-term horizon, HGR should be able to reward its shareholders with more than 38% potential returns. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 15.70
HGR's P/E(ttm) is ranked higher than
94% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 43.30 vs. HGR: 15.70 )
HGR' s 10-Year P/E(ttm) Range
Min: 9.71   Max: 253.33
Current: 15.7

9.71
253.33
Forward P/E 7.39
HGR's Forward P/E is ranked higher than
98% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 26.67 vs. HGR: 7.39 )
N/A
PE(NRI) 15.70
HGR's PE(NRI) is ranked higher than
94% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 40.70 vs. HGR: 15.70 )
HGR' s 10-Year PE(NRI) Range
Min: 9.71   Max: 1596
Current: 15.7

9.71
1596
P/B 1.55
HGR's P/B is ranked higher than
88% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 3.14 vs. HGR: 1.55 )
HGR' s 10-Year P/B Range
Min: 0.51   Max: 2.59
Current: 1.55

0.51
2.59
P/S 0.87
HGR's P/S is ranked higher than
81% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 1.73 vs. HGR: 0.87 )
HGR' s 10-Year P/S Range
Min: 0.18   Max: 1.36
Current: 0.87

0.18
1.36
PFCF 99.58
HGR's PFCF is ranked higher than
71% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 47.64 vs. HGR: 99.58 )
HGR' s 10-Year PFCF Range
Min: 2.91   Max: 124.92
Current: 99.58

2.91
124.92
POCF 17.98
HGR's POCF is ranked higher than
74% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 16.94 vs. HGR: 17.98 )
HGR' s 10-Year POCF Range
Min: 2.15   Max: 22.56
Current: 17.98

2.15
22.56
EV-to-EBIT 12.39
HGR's EV-to-EBIT is ranked higher than
91% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 23.61 vs. HGR: 12.39 )
HGR' s 10-Year EV-to-EBIT Range
Min: 7.4   Max: 52.2
Current: 12.39

7.4
52.2
PEG 1.74
HGR's PEG is ranked higher than
95% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. HGR: 1.74 )
HGR' s 10-Year PEG Range
Min: 0.49   Max: 143.24
Current: 1.74

0.49
143.24
Shiller P/E 18.46
HGR's Shiller P/E is ranked higher than
95% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 207.68 vs. HGR: 18.46 )
HGR' s 10-Year Shiller P/E Range
Min: 14.2   Max: 392
Current: 18.46

14.2
392
Current Ratio 3.94
HGR's Current Ratio is ranked higher than
97% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. HGR: 3.94 )
HGR' s 10-Year Current Ratio Range
Min: 0.44   Max: 8.75
Current: 3.94

0.44
8.75
Quick Ratio 2.45
HGR's Quick Ratio is ranked higher than
94% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. HGR: 2.45 )
HGR' s 10-Year Quick Ratio Range
Min: 0.3   Max: 7.98
Current: 2.45

0.3
7.98
Days Inventory 76.05
HGR's Days Inventory is ranked higher than
72% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 71.27 vs. HGR: 76.05 )
HGR' s 10-Year Days Inventory Range
Min: 64.95   Max: 148.49
Current: 76.05

64.95
148.49
Days Sales Outstanding 70.65
HGR's Days Sales Outstanding is ranked higher than
63% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 52.71 vs. HGR: 70.65 )
HGR' s 10-Year Days Sales Outstanding Range
Min: 50.65   Max: 132.78
Current: 70.65

50.65
132.78

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.05
HGR's Price/DCF (Projected) is ranked higher than
91% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 3.93 vs. HGR: 1.05 )
HGR' s 10-Year Price/DCF (Projected) Range
Min: 0.33   Max: 2.49
Current: 1.05

0.33
2.49
Price/Median PS Value 1.33
HGR's Price/Median PS Value is ranked higher than
71% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 1.31 vs. HGR: 1.33 )
HGR' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 3.45
Current: 1.33

0.08
3.45
Price/Peter Lynch Fair Value 1.28
HGR's Price/Peter Lynch Fair Value is ranked higher than
96% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. HGR: 1.28 )
HGR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.51   Max: 21.7
Current: 1.28

0.51
21.7
Earnings Yield (Greenblatt) 8.10
HGR's Earnings Yield (Greenblatt) is ranked higher than
90% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. HGR: 8.10 )
HGR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.9   Max: 13.6
Current: 8.1

1.9
13.6
Forward Rate of Return (Yacktman) 15.98
HGR's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 9.87 vs. HGR: 15.98 )
HGR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -944.8   Max: 36.2
Current: 15.98

-944.8
36.2

Business Description

Industry: Health Care Providers » Medical Care
Compare:CHE, FMS, DVA, FSNUY, BDUUF » details
Traded in other countries:HO8.Germany,
Hanger Inc was incorporated on March 3, 1988. The Company is a provider of services and products that enhance human physical capabilities. It provides orthotic and prosthetic patient-care services, distributes O&P devices and components, manages O&P networks, and provides therapeutic solutions to the broader post acute market. It has two operating segments: Patient Care and Products & Services. Patient Care segment is comprised of Hanger Clinic, Cares, Dosteon, other related O&P businesses and its contracting network management business. Through this segment, it is the owner and operator of orthotic and prosthetic patient care clinics in the United States and manages an O&P provider network of approximately 1,150 clinics that coordinates all aspects of O&P patient care for insurance companies. It operates in excess of 740 O&P patient care clinics located in 45 states and the District of Columbia. Products & Services segment is comprised of its distribution business, one of the largest distributors of O&P products in the United States, and its rehabilitative solutions business. Its distribution facilities in California, Florida, Georgia, Illinois, Pennsylvania and Texas allow it to deliver products to the vast majority of its distribution customers in the United States within two business days. Its rehabilitative solutions business develops specialized rehabilitation technologies and is a leading provider of evidence-based clinical programs for post-acute rehabilitation, serving more than 4,200 long-term care facilities and other sub-acute rehabilitation providers throughout the United States. This segment also develops neuromuscular technologies through independent research. The Patient Care segment competes with numerous small independent O&P providers for referrals from physicians, therapists, employers, HMOs, PPOs, hospitals, rehabilitation centers, out-patient clinics and insurance companies on both a local and regional basis. It competes with other patient care service providers, including device manufacturers that have independent sales forces, on the basis of quality and timeliness of patient care, location of patient care clinics and pricing for services. The Products & Services segment competes with other distributors, manufactures who sell their products directly, and providers of equipment and services on a regional and national basis that have similar sales forces and products. Some of its distributor competitors are also dedicated to the O&P industry, but many others are large medical product distributors who also distribute O&P products, particularly orthotic products. The Company is subject to a variety of federal, state and local governmental regulations.
» More Articles for HGR

Headlines

Articles On GuruFocus.com
John Rogers Has Busy Third Quarter Nov 12 2014 
Hanger: A favorable aging demography trend Sep 08 2014 
Hanger Orthopedic Group Inc. Reports Operating Results (10-K) Mar 11 2011 
Hanger Orthopedic Group Inc. (HGR) Executive Vice President, CFO George E Jr Mchenry sells 26,000 Sh Feb 28 2011 
John Keeley Buys CAR, HGR, NCR, DAN, SKS, FELE, NWBI, FII, MF, HHC Feb 09 2011 
Hanger Orthopedic Group Inc. (HGR) Executive Vice President, CFO George E Jr Mchenry sells 30,000 Sh Nov 22 2010 
Hanger Orthopedic Group Inc. (HGR) President and CEO Thomas F Kirk sells 10,030 Shares Nov 18 2010 
Hanger Orthopedic Group Inc. (HGR) Executive Vice President, CFO George E Jr Mchenry sells 1,525 Sha Nov 18 2010 
Hanger Orthopedic Group Inc. (HGR) President and CEO Thomas F Kirk sells 11,458 Shares Aug 13 2010 
Hanger Orthopedic Group Inc. (HGR) Executive Vice President, CFO George E Jr Mchenry sells 3,348 Sha Aug 13 2010 

More From Other Websites
Second Sight's 30% Jump Boosts Several Peers Feb 25 2015
Hanger to Amend and Reissue Financial Data; Results Delayed - Analyst Blog Feb 18 2015
HANGER, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Non-Reliance on... Feb 17 2015
Hanger Announces Restatement of Certain Previously-Issued Unaudited Interim Financial Statements Feb 17 2015
Hanger Announces Restatement of Certain Previously-Issued Unaudited Interim Financial Statements Feb 17 2015
Hanger Clinic patients first in world to be commercially fit with Triton smart ankle Feb 11 2015
The Amputee Empowerment Partners (AEP) Peer Support Program becomes AMPOWER Feb 09 2015
DEADLINE MONDAY: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Hanger, Inc. and... Jan 09 2015
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action... Jan 09 2015
HGR -- UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Hanger,... Jan 07 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Jan 06 2015
HGR SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Hanger, Inc.... Jan 05 2015
CFO Moves: PTC, Hanger, Seven West Media Jan 05 2015
INVESTOR ALERT: Investors of Hanger, Inc. With Losses of $50,000 or More Are Encouraged to Contact... Jan 05 2015
HANGER, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jan 05 2015
Thank you for another great year! Jan 01 2015
HGR SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Hanger, Inc.... Dec 29 2014
ALERT: Rosen Law Firm Reminds Hanger, Inc. Investors of Important January 12, 2015 Class Action... Dec 28 2014
Hanger, Inc. -- Moody's places Hanger's Ba3 CFR under review for downgrade Dec 18 2014
Deadline in Lawsuit for Investors in Hanger Inc (HGR) Shares Announced by Shareholders Foundation Dec 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK